Programa de avaliação nacional do conhecimento sobre prevenção da aterosclerose (PANDORA). Um questionário entre cardiologistas brasileiros sobre redução do colesterol

Arquivos Brasileiros de Cardiologia

Volumn 75, Issue 4, 2000, Pages 289-293

  Santos, Raul D ^a   Spósito, Andrei C ^b   Dos Santos, José Ernesto ^b   Fonseca, Francisco H ^b   Moriguchi, Emílio H ^b   Martinez, Tania L R ^b   Armaganijam, Dikran ^b   Timerman, Sérgio ^b   Timerman, Ari ^b   Nicolau, José C ^b   Ramires, José A F ^b  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0041638622     PISSN: 0066782X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Castelli WP. The new pathophysiology of coronary artery disease. Am J Cardiol 1998; 82: 60T-65T.
2. LaRosa JC, He J, Vupputuri S. Effect of statins on risk of coronary disease. A metaanalysis of randomized controlled trials. JAMA 1999; 282: 2340-6.
3. Scandinavian Simvastatin Survival Study Group: Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-9.
4. Shepherd J, Cobbe SM, Ford I. et al for The West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Eng J Med 1995; 333: 1301-07.
5. II Consenso Brasileiro sobre Dislipidemias, Detecção, avaliação e tratamento. Arq Bras Cardiol 1996; 67: 1-16.
6. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996; 335: 1001-09.
7. Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel and detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel II). JAMA 1993; 269: 3015-23.
8. Pyoralla K, De Backer G, Graham I, Poole-Wilson P and Wood D on behalf of the Task Force. Prevention of coronary heart disease in clinical practice. Recommendations of the Task force of the European society of Cardiology, European Atherosclerosis Society, and European Society of Hypertension. Eur Heart J 1994; 110: 121-61.
9. Roberts WC. The underused miracle drugs: The Statin drugs are to atherosclerosis what penicilin was to infectious diseases. Am J Cardiol 1996; 78: 377-8.
10. Feely J. The therapeutic gap-compliance with medication and guidelines. Atherosclerosis 1999; 147(suppl 1): S31-S7.
11. EUROASPIRE Study Group. EUROASPIRE a European Society of Cardiology survey of secondary prevention of coronary heart disease: Principal Results. Eur Heart J 1997; 18: 1569-82.
12. Smith GD, Shah E. Systematic review of dietary intervention trials to lower blood total cholesterol in free-living subjects. Br Med J 1998; 316: 1213-20.
13. Nawrocki JW, Weiss SR, Davidson MH et al. Reduction of LDL-cholesterol by 25-60% in patients with primary hypercholesterolemia by atorvastatin, a new H-MGCo-A reductase inhibitor. Arterioscler Thromb Vase Biol 1995; 15:678-82.
14. Downs JR, Clearfield M. Weiss DO, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. Results of AFCAPS/TEXCAPS. JAMA 1998; 279: 1615-22
15. Jones P, Kafonek S, Laurora I, Hunninghake D. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvaslatin in patients with hypercholesterolemia. Am J Cardiol 1998; 81: 582-7.
16. Vaughn CJ, Gotto Jr AM, Basson CT. The evolving role of statins in the management of atheroscleroris. J Am Coll Cardiol 2000; 35: 1-10.
17. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of Cardiovascular Events and Death with Pravastatin in Patients with Coronary Heart Disease and a Broad Range of Initial Cholesterol Levels. N Engl J Med 1998; 339: 1349-57.
18. Report from the Committee of Principal Investigators. A co-operative trial in the primary prevention of ischaemic heart disease using clofibrate. Br Heart J 1978; 40: 1069-18.
19. Frick MH, Elo O, Haapa K, et al. Helsinki heart study; primary prevention trial with gemfibrozil in middle-aged men with dyslipidemia. N Eng J Med 1987; 317: 1237-45.
20. Lipid Research Clinics Program. The Lipid Research Clinics Coronary Primary Prevention Trial Results. 1. Reduction in incidence of coronary heart disease. JAMA 1984; 214: 351-64.
21. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and estrogen/progestin replacement study (HERS) research group. JAMA 1998; 280: 605-13.
22. Shepherd J. Fibrates and statins in the treatment of hyperlipidaemia: an appraisal of their efficacy and safety. Eur Heart J 1995; 6: 5-13.
23. Martinez-Gonzalez MA, Bueno-Cavanillas A, Sanchez-Izquierdo F, Aguinaga Ontoso I, Jimenez-Moleon JJ, Delgado-Rodriguez M. Changes in coronary risk profiles in employees after three years of multifactorial intervention. Eur J Epidemiol 1998; 14: 653-62.
24. Grimm RH Jr. The multiple risk factor intervention trial in the U.S. A summary of results at four years in special intervention and usual care men. Prev Med. 1983; 12: 185-90.
25. Flanagan DE, Cox P, Paine D, Davies J, Armitage M. Secondary prevention of coronary heart disease in primary care: a healthy heart initiative. QJM 1999; 92: 245-50.
26. Froliks JP, Zyzanski SJ, Schwanz JM, Suhan PS. Physician noncompliance with the 1993 National Cholesterol Education Program (NCEP-ATP II) guidelines. Circulation 1998; 98: 851-5.
27. Sueta CA, Chowdhury M, Boccuzzi SJ, et al. Analysis of the degree of undertreatment of hyperlipidemia and congestive heart failure secondary to coronary artery disease. Am J Cardiol 1999; 83: 1303-07.